Aggressive pituitary adenomas--diagnosis and emerging treatments (Q38211375)

31 August 2017

title

Aggressive pituitary adenomas--diagnosis and emerging treatments (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

Luis V. Syro

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

5

Kalman Kovacs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Fabio Rotondo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

Michael D Cusimano

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

13 May 2014

1 reference

Nature Reviews Endocrinology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

423-435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821329 AND SRC:MED&resulttype=core&format=json

The pathogenesis of pituitary tumors

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pathology of invasive pituitary tumors with special reference to functional classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinical review: Diagnosis and management of pituitary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Management of aggressive pituitary adenomas: current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Atypical pituitary adenomas: incidence, clinical characteristics, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The subdiaphragmatic cistern: historic and radioanatomic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinical review: Pituitary carcinoma: difficult diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Therapy of aggressive pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Biomarkers of aggressive pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinicopathological correlations in pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Therapeutic implications of accurate classification of pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Growth patterns of pituitary adenomas and histopathological correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Biomarkers of Pituitary Neoplasms: A Review (Part II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Ki-67 in pituitary neoplasms: a review--part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Are markers of proliferation valuable in the histological assessment of pituitary tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Predictive markers of pituitary adenoma behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Acromegaly. Recognition and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Genetics and proteomics of pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Angiogenesis in normal and neoplastic pituitary tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Microvessel density in pituitary adenomas and carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

VEGF signalling: integration and multi-tasking in endothelial cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Endocan expression and localization in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

PTTG overexpression is correlated with angiogenesis in human pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Preserving fertility in prepubertal children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pituitary senescence: the evolving role of Pttg

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Increased chromosomal imbalances in recurrent pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Genetics of pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pituitary tumors in patients with MEN1 syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

A differential diagnosis of inherited endocrine tumors and their tumor counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Advances in the treatment of prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Acromegaly pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Guidelines for acromegaly management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Resistance to somatostatin analogs in acromegaly: an evolving concept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Resistance to Somatostatin Analogs in Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Treatment of pituitary tumors: pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Effects of medical therapy on pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

21 January 2018

Pathology of acromegaly

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Medical management of Cushing's disease: what is the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Gamma knife stereotactic radiosurgery of Nelson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing's disease, even in case of macroadenomas or invasive adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Treatment of nonfunctioning pituitary adenomas: what were the contributions of the last 10 years? A critical view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinical results of conformal radiotherapy and radiosurgery for pituitary adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Role of stereotactic radiosurgery in the management of pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Mechanisms of disease: temozolomide and glioblastoma--look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Optimal role of temozolomide in the treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Temozolomide in aggressive pituitary adenomas and carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Treatment of pituitary neoplasms with temozolomide: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Anti-VEGF therapy in pituitary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

New targeted therapies in pituitary carcinoma resistant to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pathogenesis of pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Transphenoidal Microsurgery of the Normal and Pathological Pituitary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Microsurgical anatomy of the diaphragma sellae and its role in directing the pattern of growth of pituitary adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Prognostic indicators in an aggressive pituitary Crooke's cell adenoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Expression of Glycoprotein Hormones and Intracytoplasmic Distribution of Cytokeratin in Growth Hormone-Producing Pituitary Adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The 2004 WHO classification of pituitary tumors: comments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Vasculature in Nontumorous Hypophyses, Pituitary Adenomas, and Carcinomas: A Quantitative Morphologic Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome

31 March 2020

2 references

https://api.crossref.org/works/10.1038/NRENDO.2014.64

31 March 2020

12 December 2020

Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Ras mutations in human pituitary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Dopamine agonist–resistant prolactinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

The Place of Pegvisomant in the Management of Acromegaly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2014.64

Clinically silent corticotroph tumors of the pituitary gland

31 March 2020

1 reference

12 December 2020

Epidemiology and etiopathogenesis of pituitary adenomas

1 reference

12 December 2020

Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas

1 reference

12 December 2020

1 reference

12 December 2020

Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.

1 reference

12 December 2020

Pituitary tumour-transforming gene (PTTG) and pituitary senescence

1 reference

12 December 2020

Management of medically refractory prolactinoma

1 reference

12 December 2020

Outcomes of surgically treated giant pituitary tumours.

1 reference

12 December 2020

ras mutations in human prolactinomas and pituitary carcinomas

1 reference

12 December 2020

Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors.

1 reference

12 December 2020

Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ?

1 reference

12 December 2020

Overexpression of endocan induces tumor formation.

1 reference

12 December 2020

Biomarkers of pituitary neoplasms.

1 reference

12 December 2020

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness

1 reference

12 December 2020

H-ras mutations in human pituitary carcinoma metastases

1 reference

12 December 2020

Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.

1 reference

12 December 2020

Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.

1 reference

12 December 2020

Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy

1 reference

12 December 2020